scispace - formally typeset
R

Robert A. Henderson

Researcher at Corixa Corporation

Publications -  42
Citations -  5742

Robert A. Henderson is an academic researcher from Corixa Corporation. The author has contributed to research in topics: Antigen & Major histocompatibility complex. The author has an hindex of 25, co-authored 41 publications receiving 5653 citations. Previous affiliations of Robert A. Henderson include Roswell Park Cancer Institute & University of Pittsburgh.

Papers
More filters
Journal ArticleDOI

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

TL;DR: Microcapillary high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry was used to fractionate and sequence subpicomolar amounts of peptides isolated from the MHC molecule HLA-A2.1.
Journal ArticleDOI

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines

TL;DR: Melanoma-specific CTLs had an exceptionally high affinity for this nine-residue peptide, which reconstituted an epitope for CTL lines from each of five different melanoma patients tested.
Journal ArticleDOI

HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation.

TL;DR: Results suggest that proteolysis of signal peptide domains in the endoplasmic reticulum is a second mechanism for processing and presentation of peptides for association with class I molecules.
Journal Article

Activation of human dendritic cells following infection with Mycobacterium tuberculosis.

TL;DR: Data indicate that infection with M. tuberculosis results in the direct activation and maturation of DC, which may facilitate migration to the lymph nodes, and enhance presentation of Ag to T cells, thereby facilitating the induction of the immune response against this pathogen.
Journal ArticleDOI

MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines

TL;DR: Recognized as a native molecule independent of MHC, MUC-1 is a universal immunogen and a universal target, and if made effectively immunogenic, it would be expected to elicit immune responses in all patients, and against numerous M UC-1 expressing human tumors.